Longer-Term Real-World Data Needed to Compare Leqembi and Kisunla Opposing Treatment Strategies for Alzheimer’s

Why It Matters

Understanding which strategy delivers sustained clinical benefit at manageable cost will shape payer coverage, provider adoption, and future Alzheimer’s drug development.

Key Takeaways

• Leqembi shows 9.8‑month progression delay at four years
• 73% of early AD patients had stable CDR‑SB scores
• Leqembi Iqlik SC formulation enables home administration
• Kisunla may stop after amyloid clearance without rapid rebound
• Long‑term real‑world data needed to compare strategies

Pulse Analysis

The Alzheimer’s therapeutic landscape is now defined by two anti‑amyloid monoclonal antibodies that embody contrasting philosophies. Leqembi (lecanemab) is positioned for indefinite use, with four‑year trial data indicating a near‑10‑month postponement of disease progression and a high proportion of patients maintaining stable cognitive scores. The recent approval of its subcutaneous formulation, Leqembi Iqlik, promises to reduce infusion‑center visits, potentially improving adherence and lowering overall treatment costs for health systems.

Conversely, Lilly’s Kisunla (donanemab) is marketed as a finite regimen, aiming to halt treatment once sufficient amyloid clearance is achieved. Early data suggest that patients who reach this biomarker threshold can discontinue therapy without immediate amyloid rebound, while those who do not clear amyloid can continue dosing to achieve it. The company’s TRAILBLAZER‑ALZ 2 Addendum 11 study will monitor amyloid re‑accumulation over three additional years, addressing critical questions about re‑initiation protocols and monitoring frequency.

Both approaches hinge on long‑term real‑world evidence to resolve lingering uncertainties around safety, durability of benefit, and economic viability. Payers, clinicians, and patients will weigh continuous versus time‑limited exposure, factoring in drug acquisition costs, administration logistics, and quality‑of‑life impacts. As real‑world data accrue, they will inform not only reimbursement decisions but also the broader strategic direction of Alzheimer’s research, potentially guiding next‑generation DMT development toward personalized, outcome‑driven treatment pathways.